



**Table S1** Sequences of primers for qPCR.


<b>Gene</b>	<b>Sequence</b>	
<b>SLC7a11</b>	Forward: 5'-TCTCAAAGGAGGTTACCTGC-3' Reverse: 5'-AGACTCCCCTCAGTAAAGTGAC-3'	
<b>GPX-4</b>	Forward: 5'-TGTGGGCATCAATGGATTTGG-3' Reverse: 5'-ACACCATGTATTCCGGGTCAAT-3'	
<b>Bax</b>	Forward: 5'-CCCGAGAGGTCTTTTTCCGAG-3' Reverse: 5'-CCAGCCCATGATGGTTCTGAT-3'	
<b>Bcl-2</b>	Forward: 5'-GGTGGGGTCATGTGTGTGG-3' Reverse: 5'-CGG TTCAGG TACTCAGTCATCC-3'	
<b>GAPDH</b>	Forward: 5'-TGTGGGCATCAATGGATTTGG-3' Reverse: 5'-ACACCATGTATTCCGGGTCAAT-3'	




**Figure S1** Preparation of Apo-Lf: (A) Diagrammatic sketch of preparation of Apo-Lf from Holo-Lf. (B) Relative iron content measured by ICP-MS (n = 3). (C) Coomassie blue staining of Apo-Lf and Holo-Lf (40  $\mu$ g) after 12% SDS PAGE electrophoresis. (D) Western blotting image of Apo-Lf and Holo-Lf. Data were shown as mean $\pm$ SD. (e) Fourier transformation infrared spectrometry (FTIR) of Apo-Lf and Holo-Lf. \*\*Compared Holo-Lf group  $P < 0.01$ .



**Figure S3** qPCR analysis of MDA-MB-231 and MCF-7 cells: (A) Relative gene expression level of SLC7a11, GPX-4, Bax and Bcl-2 in MDA-MB-231 after different treatments (n = 3). (B) Relative gene expression level of SLC7a11, GPX-4, Bax and Bcl-2 in MCF-7 after different treatments. Relative gene expression level was normalized to the expression level of appropriate gene in cells treated with DMSO (n = 3). (C) Relative gene expression level of GPX-4 between MDA-MB-231 and MCF-7 cells (n = 4). Relative gene expression level was normalized to the GPX-4 mRNA expression of MDA-MB-231 cells. Data were shown as mean±SD. \*Compared with DMSO group  $P < 0.05$ . \*\*Compared with DMSO group or MDA-MB-231 cells  $P < 0.01$ . #Compared with erastin group  $P < 0.05$ . ##Compared with erastin group  $P < 0.01$ .



**Figure S4** (A) The absorbance of H<sub>2</sub>O<sub>2</sub> at 666 nm after incubated with PBS, Apo-Lf and Holo-Lf (n = 5). (B) Relative HIF-1 $\alpha$  expression level of MDA-MB-231 cells after different treatments (n = 4). Total grey intensity of each protein was normalized to the grey intensity of appropriate protein in cells treated with PBS cultured in hypoxia condition. \*\*Compared with hypoxia cells treated with PBS  $P < 0.01$ . ##Compared with hypoxia cells treated with Apo-Lf  $P < 0.01$ . (C) Tumor average total sO<sub>2</sub> of MDA-MB-231 tumor bearing mice injected with PBS, Apo-Lf and Holo-Lf at different time points (n = 5). (D) Percentage of HIF-1 $\alpha$  positive areas (n = 4). (E) Percentages of hypoxia positive areas (n = 4). \*\*Compared with PBS group  $P < 0.01$ . ##Compared with Apo-Lf group  $P < 0.01$ .



**Figure S5** (A) Quantitative analysis of major organs radiation activities 24 h after i.v. injected with  $^{125}\text{I}$  labeled Holo-Lf ( $n = 3$ ). (B) Body weight changing curves of mice treated with PBS, 4 Gy, Apo-Lf+4 Gy and Holo-Lf+4 Gy ( $n = 4$ ). (C) Survival rates of mice treated with PBS, 4 Gy, Apo-Lf+4 Gy and Holo-Lf+4 Gy ( $n = 4$ ). (D) H&E stained images of major organs obtained from different treatment groups: heart, liver, spleen, lung, and kidney. (E) GPX-4 expression was detected by IHC in mouse tumor tissues of each group. Data were shown as mean $\pm$ SD.